IMU Imugene Ltd
- 0.054
- +0.002+3.85%
Imugene Ltd News
Breakeven On The Horizon For Imugene Limited (ASX:IMU)
ASX Market Update: Telcos Strong in Weak Market | 10 July 2024
Imugene Commences Patient Dosing in Phase 1 Bile Tract Cancer Trial; Shares Up 8%
2 ASX Shares Roaring Higher on Big News
Imugene Doses First Patient for VAXINIA Bile Tract Cancer Trial in Melbourne
Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%
Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?
Those Who Invested in Imugene (ASX:IMU) Five Years Ago Are up 361%
Broker Says This ASX Biotech Stock Could Almost Double in Value
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million
AU Morning Wrap: ASX Falls in All Sectors; Star Plunges
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study
Press Release: Imugene's Oncolytic Virotherapy VAXINIA and B Cell Immunotherapy HER-Vaxx Featured at the AACR Annual Meeting 2024
Imugene Shines at AACR With Promising Cancer Therapy Results From VAXINIA and HER-Vaxx
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China
Imugene Has VAXINIA Technology Selected for Presentation at Cholangiocarcinoma Foundation Conference | ASX:IMU, OTC:IUGNF
Arovella Therapeutics' ALA-101-onCARlytics Collaboration With Imugene Ends; Shares Down 12%
Imugene's Phase 1 OnCARlytics Trial to Commence Combination Arm Treatment
Imugene's OnCARlytics Clears Phase 1 Milestone in Solid Tumour Therapy Trial
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending
Analysis
Price Target
No Data
